https://doi.org/ 10.33472/AFJBS.6.10.2024.4489-4503

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

The Importance of Predicting Drug-Receptor Interactions in the Field of Computational Drug Design

Dr. Farah Deeba[1], Dr. Jyoti Pandey[2], Himani Hirvey[3], Chintan P. Somaiya[4], Darshan J C[5], Surya Pratap Singh[6], Dr. Neelam Basera[7], Dr. Sushil Kumar Shukla[8], Habibullah Khalilullah[9]*, Suraj Mandal[10]

[1]Assistant Professor, Sharda University, Plot No 32,34, Knowledge Park-III, Greater Noida, Ruhallapur, Uttar Pradesh 201310.

[2]Assistant Professor, Faculty of Pharmacy, Medi-Caps University, Pigdamber Rau, Indore PIN- 453331

[3]Assistant Professor, MediCaps University, Rau Indore

[4]Assistant Professor, Department of Chemical Science, Parul Institute of Applied Sciences, Parul University, Vadodara, 391760, Gujarat (India)

[5]Assistant Professor, Yenepoya Pharmacy College & Research Centre, Yenepoya Deemed to be University, Ayush Campus, Naringana, Mangaluru, 575018

[6]Research Scientist-1(B), MRU, Uttar Pradesh University of Medical Sciences (UPUMS). Saifai, Etawah, (U.P.) Pin Code: 206130.

[7]Assistant Professor, School of Agriculture Graphic Era Hill University Clement Town Dehradun Uttarakhand Pincode 248001

[8]Professor & Co-Ordinator (Multi-Disciplinary Research Unit), MRU, Uttar Pradesh University of Medical Sciences (UPUMS), Saifai,Etawah,(U.P.) Pin Code: 206130.

[9]Associate Professor, Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Unaizah 51911, Qassim University, Saudi Arabia

[10]Assistant Professor, Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, U.P., India, 250001

Corresponding Author Details:

Habibullah Khalilullah, Associate Professor, Department of Pharmaceutical Chemistry and Pharmacognosy, Unaizah College of Pharmacy, Unaizah 51911, Qassim University, Saudi Arabia

Email: shabib79@gmail.com

Article History
Volume 6,Issue 10, 2024
Received:28 Apr 2024
Accepted : 25 May 2024
doi: 10.33472/AFJBS.6.10.2024.4489-4503

Abstract

Drug advancement depends vigorously on the compelling identification of potential interactions among prescriptions and proteins. Finding these relationships is as yet tedious and asset serious, even following quite a while of trial research. Thus, various PC strategies have been created to gauge drug-target correlations for an expansive scope. In this work, we give a profound learning-based way to deal with foresee drug-target interactions dependent just upon protein succession information and drug structures. With exactness paces of up to 92.2% for GPCRs, 90.2% for nuclear receptors, 92.2% for ion channels, and 90.7% for enzymes in our dataset, our discoveries show the viability of our technique. Urgently, on normal benchmark datasets, our model outflanks present status of-the-workmanship computational procedures. Additionally, the findings of our experiments demonstrate the potential of our method to identify tiny yet important characteristics, which makes it a useful tool in the hunt for novel medications.

Keywords: *Predicting Drug-Receptor, Computational Drug Design, GPCR, Enzyme, Ion Channel, Nuclear receptor.*

1. INTRODUCTION

In the realm of drug development, accurately predicting interactions between medications and target proteins is paramount. Recently, researchers have shifted focus towards innovative approaches for drug design, leveraging insights from existing medications [1] [2]. Given that most drugs interact with one or more proteins to exert their therapeutic effects, the precise identification of these proteins is crucial to avoid adverse side effects and advance the development of new therapies [3].

The identification of Drug-Target Interactions (DTIs) is pivotal for expediting the discovery of novel medications, considering the high costs and lengthy experimental processes associated with DTI identification [4] [5]. Computational techniques have emerged as a solution to this challenge, offering the ability to predict potential DTIs swiftly [6] [7]. These computational methods yield valuable insights into pharmacological mechanisms, and broadly fall into three categories: docking-based, chemogenomic-based, and ligand-based approaches, each with its own strengths and limitations [8].

Ligand-based methods, for instance, prove useful in the absence of three-dimensional structural data, though they require substantial data and computational resources [9] [10]. Docking-based techniques, while computationally intensive, offer a more realistic representation of drug-protein interactions, albeit constrained by the absence of complete structural information [11]. Chemogenomic-based approaches, on the other hand, excel in identifying analogs within medications and provide extensive coverage of chemical space [12] [13]. Additionally, they facilitate the discovery of related medications and simplify the establishment of structure-activity relationships [14] [15-35]. The fusion of computational methodologies with traditional

drug development approaches holds promise in expediting the discovery of new medications, paving the way for more effective and safer therapeutic interventions.

2. DRUG-TARGET RELATIONSHIPS

Cellular proteins, which selectively interact with chemical molecules to cure or diagnose diseases, make up the bulk of therapeutic targets. Recent research has demonstrated that around 130 protein families, including enzymes, nuclear hormone receptors, GPCRs, ion channels, and transporters, are present in conventional therapeutic drug targets. Estimating the overall number of drug targets has been the subject of several attempts. Only a tiny portion of the 6000–8000 sites thought to be of pharmacological importance in the human genome have thus far been linked to authorized medications. There are still many potential pharmacological targets that need to be verified.

From the perspective of drugs, only around 7000 compounds have the information on their respective target proteins, despite the fact that the PubChem database is thought to have 35 million chemicals. Moreover, it is predicted that more than 10 60 substances make up the collection of all conceivable tiny molecules. The majority of these medications that have matching target proteins are tiny chemical compounds that interact with the right target protein implicated in a particular illness to either block or stimulate the target protein's biological activity. Drugs may interact with proteins other than their primary therapeutic targets in addition to their selected targets; these interactions are known as off-target effects.

In the drug development process, accurately identifying and validating drug-target interactions is the initial step. Numerous possible drug-target interactions remain unidentified to this day. Because of our poor understanding of the intricate interaction between chemical and genomic spaces, finding new medications and their targets remains a very challenging task. Numerous chemical linkages that are connected to a medication's affinity for its targets are among the numerous variables that influence the development of interactions between a drug and its targets. However, there are several reasons why it is now more important than ever to identify drug-target interactions. First off, despite the fact that an increasing number of compounds have been created in the last ten years, their target proteins and medicinal effects remain unknown. Second, a number of diseases continue to be incurable and several new illnesses are discovered each. Lastly, researchers have gathered significant data sets on a variety of chemical properties, target protein characteristics, and physiological system reactions in humans. However, because of their high dimensionality, intricate structure, and variety of sorts, these high-dimensional data sets pose significant problems to researchers. At present, limited scope research is the best way to direct trial verification of drug-target interactions because of the intricacy of the relationships between many target proteins and prescriptions, which takes time and cash. Subsequently, there is a squeezing need for reasonable and strong computational prediction procedures that can effectively distinguish the multifaceted drug-target relationships for an expansive scope. The detection of computational drug-target interactions might assist with facilitating the quest for new drugs and advance human medication, as well as increment our insight into perplexing organic relationships and huge natural cycles. Computational science has zeroed in on the prediction of conceivable drug-target interactions from heterogeneous organic information, which can possibly diminish the time and cost of natural examinations and create new drug-target interaction contender for natural analysis validation.

3. RESEARCH METHODOLOGY

3.1.Data Collection

This paper investigates possible drug-target protein interactions using three benchmark datasets. The Drug Bank database provided two of these datasets, while the KEGG DRUG database provided the third. KEGG DRUG catalogs a wide range of approved drugs in the USA, Europe, and Japan, many of which include information on target proteins. It does this by using information on synthetic designs and atomic interaction organizations. In the in the meantime, Drug Bank offers the public helpful assets, like information on 2555 endorsed little particle medications and 5121 careful non-repetitive successions of target proteins.

There are 4797 drug-target matches in Dataset1, the first dataset, of which 2719 incorporate enzymes, 1372 ion channels, 630 GPCRs, and 86 nuclear receptors. Negative samples were chosen at random in order to preserve a 2:1 ratio of negative to positive samples. Positive samples were identified. The second DTI dataset, Dataset 2, was assembled by hand, merging enzymes with protein kinases and eliminating medications without structural details or target proteins without primary sequences. Furthermore, duplicate drug-target combinations from Dataset 2 were eliminated. Maintaining a 2:1 ratio of negative to positive samples, Dataset2 exhibited similar characteristics to Dataset1, yielding 16140 drug-target pairings, 3629 of which involved enzymes, 5513 ion channels, 5957 GPCRs, and 1049 nuclear receptors.

Figure 1 outlines the amounts of medications, target proteins, and drug-target matches utilizing Datasets 1 and 2. For additional subtleties, allude to Additional record 1.



(a)



(b)



(c)

Figure 1: The two benchmark datasets (Dataset1 and Dataset2)'s statistical distribution of pharmaceuticals, targets, and drug-target pairings.

The last dataset, designated as Dataset3, was not included in the research since it contained either very tiny molecules or inorganic compounds. This dataset, which included 6262 positive examples and an equivalent number of negative examples, was made by means of irregular selection. This implies that 12524 potential drug-target combinations were utilized in this review.

3.2. Drug-Related Visuals

A collection of fixed-length numbers known as sub-atomic descriptors gives an emblematic representation of small particles that hold significant synthetic information. These descriptors are generally used to work with a few drug revelation procedures in cheminformatics applications, like drug ADME/T prediction, virtual screening, and QSAR examination, among others. These substance little particle descriptors are registered utilizing the Java programming language by PaDEL-Descriptor, a graphical UI (GUI) tool kit. It professes to be viable with a wide range of frameworks. As of this moment, it has 1,440 two-and one-dimensional highlights, 134 three-dimensional qualities, and 10 exceptional unique mark sorts. It is feasible to address the 1,444-dimensional 1D and 2D descriptors that were utilized in this investigation to portray the drug applicants as D = D1, D2, D3,..., D1444.

3.3. Protein Illustrations

Target protein successions encode various amino corrosive physicochemical properties that are incredibly valuable for guaging drug-target interactions (DTIs). 34 qualities from the AAindex1 data set with correlation coefficients under 0.5 were eliminated to further develop the last prediction execution. Correlation coefficients between trait matches were determined and arranged all through this methodology. For each trademark, the quantity of characteristics with correlation coefficients more prominent than 0.5 was then recorded and submitted in sliding request. From that point onward, the characteristics that had correlation coefficients more than 0.5 with the first quality were disposed of individually, starting with the property that had the most elevated correlation and working downhill. After this cycle was done, 34 qualities were kept.

These chose ascribes were used by the Moran autocorrelation descriptors method to encode protein targets. Moran autocorrelation, broadly utilized in predicting helix contents, basically assesses the impact of adjoining amino acids on a given focal amino corrosive. The encoded Moran autocorrelation descriptors for target proteins, indicated as T, are communicated as follows:

$$T\left(d\right) = \frac{\frac{1}{N-d}\sum_{i=1}^{N-d}\left(P_i - \overline{P}\right)\left(P_{i+d} - \overline{P}\right)}{\frac{1}{N}\sum_{i=1}^{N-d}\left(P_i - \overline{P}\right)^2}$$

3.4. Neural Convolution

Convolutional Neural Organizations (CNNs) are a strong profound learning engineering that are generally utilized in various fields, including picture and video identification, regular language handling, and recommender frameworks. Additionally, these organizations have shown guarantee in the logical areas of drug revelation and neuronal layer segmentation. CNNs impersonate the mental function of human mind frameworks by emulating the organization of neural connections, which is propelled by natural cycles.

Rather than conventional multi-facet perceptron (MLPs), CNNs furnish a more profound organization with less boundaries, taking care of issues like vanishing or expanding slopes in backpropagation. A few layers make up a standard CNN design, including convolutional, pooling, and completely connected layers. A collection of learnable channels or pieces that

slide over a framework or vector to make include maps characterize the convolutional layer, the principal part of CNNs.

After each convolutional layer, a technique known as pooling is oftentimes used to accelerate union and eliminated calculation time by consolidating replies from a few regions to further develop flexibility to spatial changes. The weight grid W1 and the predisposition vector b1 are the main two teachable boundaries that influence the results of any layer V1 and its past layer (V1 - 1). This strategy is completed in the accompanying way:

$$\mathbf{V}_l = pool(f(\mathbf{V}_{l-1} * \mathbf{W}_l + \mathbf{b}_l)),$$

Here, f (·) stands for the activation function, "pool" for the max-pooling procedure, and (*) for the convolution operation.

A dropout layer is utilized as a regularization way to deal with forestall overfitting. It works by adding arbitrary commotion to the secret layers, where hubs that are set apart as "exited" are excluded from the forward pass or backpropagation. The completely associated layer in profound neural organization structures ordinarily alludes to the last layers, where each neuron is associated with each and every hub in the layers that precede and after it.



Figure 2: shows the CNN-based prediction model with one convolutional layer and one pooling layer added, all as per the LeNet-5 structure's design standards. Since LeNet-5 has relatively less boundaries than other profound learning calculations, this study involves it as a gauge.

3.5. Building a Model Utilizing Convolutional Neural Organizations

An information augmentation technique was utilized due to the limitations of a little dataset in profound learning model preparation and its conceivable impact on generalization. To start with, let us take a gander at the [D,T] representation of a potential drug-target combination. This vector is just the concatenation of two vectors of dimensions 442: D=[D1,D2,D3,… ,D342] for prescriptions and T=[T1,T2,T3,… ,T442] for protein descriptors. In our preparation model, our methodology thinks about all target proteins and small substance compounds. Guaranteeing that medication vectors generally compare with target vectors diminishes predispositions coming about because of variations in vector counts, making it simpler and more impartial to prepare a reasonable model for DTI detection.

The 342-dimensional drug vector for each drug-target combination (i.e., [D, T] = [D1, D2, D3,... D342, T1, T2, T3,... T442]) was made by arbitrary selection, as displayed in Figure 3. Then, at that point, n sets of drug vectors were associated with the 442-dimensional target descriptors by rehashing this system. In this manner, n sets of made drug-target matches

(Vn=[Dn,T]1×784, n=1,2,...), each containing n unmistakable drug vectors haphazardly picked, were joined to make a solitary drug-target pair. The cycle was halted after 40,000-50,000 drug-target pairings had been made generally. As subsequently, a solitary drug-target combination was portrayed by utilizing the n-times pairings.



Figure 3: a flowchart showing how convolutional neural networks (CNN) are used to predict drug-target interactions (DTIs). The end results are shown by 0 and 1, respectively, for DTI and non-DTI cases.

Subsequently, each drug-target combination's properties were organized into a 28x28 matrix, similar to what happens in digital image identification, to make training a predictive model with the CNN technique easier. Utilizing the outfit of prediction values from n-times pairings, the last predictions were created. If half or a greater amount of the n-matches in the gathering were recognized as certain examples, a drug-target pair is supposed to collaborate; on the off chance that not, the pair is considered non-connecting. Fig. 3 shows how our model pipeline was assembled.

4. DATA ANALYSIS AND RESULTS

4.1. Evaluating the Predictive Performance for Drug-Target Interactions

Drug classifications partition target proteins into four different drug-target groupings. We utilized 10-overlap cross-validation to make four free indicators with reliable boundaries to assess the presentation of our models. Basically, 10 unmistakable subsets were haphazardly chosen from our dataset. A big part of the subset was utilized for preparing, while the other half was designated as the test set. 10 iterations of this method were completed, with 10 repetitions for each case.

Utilizing Dataset 2, the model was first prepared to recognize Drug-Target Interactions (DTIs). Table 1 shows that for each of the four DTI classes on Dataset 2, the model accomplishes Region Under the Bend (AUC) values and correctnesses over 0.90. With a F1 score of 0.883, awareness of 0.883, precision of 0.880, and AUC worth of 0.975, the enzyme model performs

obviously superior to the others. The best exactness values are accomplished by the GPCR and enzyme gatherings (Acc=0.922).

It is essential that GPCRs present an obstacle in DTI identification due to our unfortunate comprehension of their three-dimensional calculations. This challenge comes from any unidentified or befuddling attributes that influence the characterization of GPCR targets. In any case, the discoveries show that our methodology is successful in separating DTIs including GPCRs.

Table 1: Presents the detailed performance of the four protein families through 10-fold cross-validation on Datasets 1 and 2.

Type	Dataset	Acc	Sen	Pre	F1	AUC
Enzyme	Dataset1	0.945	0.929	0.905	0.917	0.987
	Dataset2	0.922	0.883	0.882	0.883	0.975
Channels of ions	Dataset1	0.921	0.896	0.869	0.883	0.972
	Dataset2	0.902	0.95	0.794	0.865	0.951
GPCRs	Dataset1	0.886	0.82	0.833	0.826	0.947
	Dataset2	0.922	0.901	0.868	0.884	0.97
Nuclear Receptors	Dataset1	0.886	0.874	0.8	0.835	0.938

The Recipient Working Trademark (ROC) bends for the four drug-target interaction classes in Datasets 1 and 2 are displayed in Figure 4. These bends infer that our profound learning-based model, which we have recommended, effectively separates qualities to distinguish genuine drug-target interactions with low bogus positive rates and high obvious positive rates at all edges.



Figure 4: We directed an investigation of the Collector Working Trademark (ROC) bends produced by our model utilizing Datasets 1 and 2 across different classifications of Drug-Target Interactions (DTI), in particular enzymes, ion channels, G protein-coupled receptors (GPCRs), and nuclear receptors.

We did a correlation examination against state of the art AI techniques, for example, k-Closest Neighbor (KNN) and Irregular Woodlands (RF), with a specific spotlight on G protein-coupled receptors (GPCRs) in Dataset 1. This permitted us to additionally exhibit the flexibility and trustworthiness of our methodology. By applying the most ideal hyperparameters for every calculation, agreeable outcomes were gotten. While RF had the option to arrive at a greatest precision of 0.878, Table 2 shows that our strategy performs better compared to existing AI calculations as far as responsiveness, exactness, F1 score, and AUC esteem.

F1 score, which is important for DTI predictions because it strikes a compromise between accuracy and sensitivity, supported our approach. With an AUC of 0.968, we outperformed KNN by 11.4% and RF by 1.7% respectively. Interestingly, our model performed better than other machine learning techniques when tested on the same dataset, indicating the advantage of deep learning in managing the complexity involved in classifying drug-target interactions.

Table 2: Comparison of GPCR classification with alternative machine learning techniques

Methods	Acc	Sen	Pre	Fl	AUC
Our framework	0.922	0.902	0.868	0.884	0.97
KNN	0.832	0.854	0.704	0.772	0.899
Unexpected Woods	0.914	0.858	0.88	0.869	0.96

4.2. Rate of learning

In our study, we investigated learning rates (lr) of 0.03, 0.003, and 0.0003 for Convolutional Neural Networks (CNN). The choice of learning rate significantly influences the overall performance of CNN, emphasizing the importance of finding an optimal value across various datasets. A high learning rate can lead to loss, hindering the extraction of useful features, while a low learning rate may cause slow convergence, prolonging training time and potentially degrading performance. Notably, setting the learning rate to 0.03 resulted in a loss for the model, rendering it unsuitable for inclusion in this analysis.

4.3. Layer of batch normalization

Batch normalization (BN) is a fundamental technique in deep learning, streamlining model training and convergence. Its inclusion is crucial for optimizing deep learning processes. Models lacking a BN layer often experience significantly higher error rates due to the unreliability of their output distributions. Our study revealed that Convolutional Neural Network (CNN) architectures incorporating BN layers consistently outperformed those without, particularly in terms of generalizability, thus mitigating the risk of encountering unoccupied loss. Leveraging BN enables our model to effectively normalize data, facilitating accurate predictions of input occurrences as either interactions or non-interactions.

5. DISCUSSION

Inspired by the above results, this section tackles three recurrent issues that probably affected our suggested model's ability to anticipate outcomes.

One important factor evaluated by the loss value during CNN training is the convergence of our model, which indicates the amount of time needed for it to learn the features needed to correctly predict relationships between drugs and target proteins. Because the settings were applied consistently, similar loss patterns were seen in all four types of Drug-Target Interactions (DTIs) (see Fig. 5). Interestingly, all four classes' loss values significantly decreased throughout the first 1000 iterations, translating to accuracies of about 85%. The loss then rapidly decreased as the number of repetitions increased. The loss values settled within a small range of 0.1 by the 40,000th iteration. This illustrates our model's favorable quick convergence time and skillful prediction abilities across the various DTI classes.



Figure 5: The loss function curves for the four distinct types of Drug-Target Interactions (DTIs)

6. CONCLUSION

The computational prediction of drug-target interactions has become progressively significant in drug improvement since the trial detection of these interactions is work escalated and tedious. In this work, we give areas of strength for a based classifier that simply requires 1D and 2D primary representations of drug and protein groupings to recognize genuine interaction pairings. We utilized specific drug descriptors that were picked aimlessly and encoded all target protein descriptors into a picture like network, involving them as information vectors, to depict unmistakable drug-target pairings. By training on three different benchmark datasets, our CNN system was able to detect drug-target interactions more accurately than prior baseline approaches, leading to more accurate predictions. This demonstrates how well our CNN architecture extracts valuable characteristics from large datasets. Going forward, we believe that deep learning techniques will become the standard way to find possible drug-target protein correlations across a range of drug research fields.

REFERENCES

1. *Abagyan R, Lee WH, Raush E, Budagyan L, Totrov M, Sundstrom M, Marsden BD. (2006) Disseminating structural genomics data to the public: from a data dump to an animated story. Trends Biochem Sci 31:76–78 [PubMed] [Google Scholar]*
2. *Abagyan R, Totrov M,, Kuznetsov D. (1994) ICM - a new method for protein modeling and design–applications to docking and structure prediction from the distorted native conformation. J Comput Chem 15:488–506 [Google Scholar]*
3. *Abrams CF, Vanden-Eijnden E. (2010) Large-scale conformational sampling of proteins using temperature-accelerated molecular dynamics. Proc Natl Acad Sci USA 107:4961–4966 [PMC free article] [PubMed] [Google Scholar]*
4. *Accelrys (2013) Accelrys metabolite. Available from http://accelrys.com/products/databases/bioactivity/metabolite.html*
5. *Acharya C, Coop A, Polli JE, Mackerell AD., Jr (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7:10–22 [PMC free article] [PubMed] [Google Scholar]*
6. *Agarwal AK, Fishwick CW. (2010) Structure-based design of anti-infectives. Ann N Y Acad Sci 1213:20–45 [PubMed] [Google Scholar]*
7. *Agnese V, Bazan V, Fiorentino FP, Fanale D, Badalamenti G, Colucci G, Adamo V, Santini D, Russo A. (2007) The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 18 (Suppl 6):vi47–vi52 [PubMed] [Google Scholar]*
8. *Ahlström MM, Ridderström M, Zamora I. (2007. a) CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. J Med Chem 50:5382–5391 [PubMed] [Google Scholar]*
9. *Ahlström MM, Ridderström M, Zamora I, Luthman K. (2007. b) CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. J Med Chem 50:4444–4452 [PubMed] [Google Scholar]*
10. *Al-Sha'er MA, Taha MO. (2010) Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors. J Chem Inf Model 50:1706–1723 [PubMed] [Google Scholar]*

11. *Alguacil LF, Pérez-García C. (2003) Histamine H3 receptor: a potential drug target for the treatment of central nervous system disorders. Curr Drug Targets CNS Neurol Disord 2:303–313 [PubMed] [Google Scholar]*
12. *Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722 [PMC free article] [PubMed] [Google Scholar]*
13. *Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. (1990) Basic local alignment search tool. J Mol Biol 215:403–410 [PubMed] [Google Scholar]*
14. *Amaro RE, Schnaufer A, Interthal H, Hol W, Stuart KD, McCammon JA. (2008) Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei. Proc Natl Acad Sci USA 105:17278–17283 [PMC free article] [PubMed] [Google Scholar]*
15. *An JH, Lee DCW, Law AH, Yang CL, Poon LL, Lau AS, Jones SJ. (2009) A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase. J Med Chem 52:2667–2672 [PubMed] [Google Scholar]*
16. Mandal S, Vishvakarma P. Nanoemulgel: A Smarter Topical Lipidic Emulsion-based Nanocarrier. Indian J of Pharmaceutical Education and Research. 2023;57(3s):s481-s498.
17. Mandal S, Jaiswal DV, Shiva K. A review on marketed Carica papaya leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. International Journal of Pharmaceutical Research. 2020 Jul;12(3).
18. Bhandari S, Chauhan B, Gupta N, et al. Translational Implications of Neuronal Dopamine D3 Receptors for Preclinical Research and Cns Disorders. *African J Biol Sci (South Africa)*. 2024;6(8):128-140. doi:10.33472/AFJBS.6.8.2024.128-140
19. Tripathi A, Gupta N, Chauhan B, et al. Investigation of the structural and functional properties of starch-g-poly (acrylic acid) hydrogels reinforced with cellulose nanofibers for cu2+ ion adsorption. *African J Biol Sci (South Africa)*. 2024;6(8): 144-153, doi:10.33472/AFJBS.6.8.2024.141-153
20. Sharma R, Kar NR, Ahmad M, et al. Exploring the molecular dynamics of ethyl alcohol: Development of a comprehensive model for understanding its behavior in various environments. Community Pract. 2024;21(05):1812-1826. doi:10.5281/zenodo.11399708
21. Mandal S, Kar NR, Jain AV, Yadav P. Natural Products As Sources of Drug Discovery: Exploration, Optimisation, and Translation Into Clinical Practice. African J Biol Sci (South Africa). 2024;6(9):2486-2504. doi:10.33472/AFJBS.6.9.2024.2486-2504
22. Kumar S, Mandal S, Priya N, et al. Modeling the synthesis and kinetics of Ferrous Sulfate production: Towards Sustainable Manufacturing Processes. African J Biol Sci (South Africa). 2024;6(9):2444-2458. doi:10.33472/AFJBS.6.9.2024.
23. Revadigar RV, Keshamma E, Ahmad M, et al. Antioxidant Potential of Pyrazolines Synthesized Via Green Chemistry Methods. African J Biol Sci (South Africa). 2024;6(10):112-125. doi:10.33472/AFJBS.6.10.2024.112-125
24. Sahoo S, Gupta S, Chakraborty S, et al. Designing, Synthesizing, and Assessing the Biological Activity of Innovative Thiazolidinedione Derivatives With Dual Functionality. African J Biol Sci (South Africa). 2024;6(10):97-111. doi:10.33472/AFJBS.6.10.2024.97-111

25. Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its Future Prospective. Indian J of Pharmaceutical Education and Research. 2024;58(1):45-63.

26. Mishra, N., Alagusundaram, M., Sinha, A., Jain, A. V., Kenia, H., Mandal, S., & Sharma, M. (2024). Analytical Method, Development and Validation for Evaluating Repaglinide Efficacy in Type Ii Diabetes Mellitus Management: a Pharmaceutical Perspective. Community Practitioner, 21(2), 29–37. https://doi.org/10.5281/zenodo.10642768

27. Singh, M., Aparna, T. N., Vasanthi, S., Mandal, S., Nemade, L. S., Bali, S., & Kar, N. R. (2024). Enhancement and Evaluation of Soursop (Annona Muricata L.) Leaf Extract in Nanoemulgel: a Comprehensive Study Investigating Its Optimized Formulation and Anti-Acne Potential Against Propionibacterium Acnes, Staphylococcus Aureus, and Staphylococcus Epidermidis Bacteria. Community Practitioner, 21(1), 102–115. https://doi.org/10.5281/zenodo.10570746

28. Khalilullah, H., Balan, P., Jain, A. V., & Mandal, S. (n.d.). Eupatorium Rebaudianum Bertoni (Stevia): Investigating Its Anti-Inflammatory Potential Via Cyclooxygenase and Lipooxygenase Enzyme Inhibition - A Comprehensive Molecular Docking And ADMET. Community Practitioner, 21(03), 118–128. https://doi.org/10.5281/zenodo.10811642

29. Mandal, S. Vishvakarma, P. Pande M.S., Gentamicin Sulphate Based Ophthalmic Nanoemulgel: Formulation and Evaluation, Unravelling A Paradigm Shift in Novel Pharmaceutical Delivery Systems. Community Practitioner, 21(03), 173-211. https://doi.org/10.5281/zenodo.10811540

30. Mandal, S., Tyagi, P., Jain, A. V., & Yadav, P. (n.d.). Advanced Formulation and Comprehensive Pharmacological Evaluation of a Novel Topical Drug Delivery System for the Management and Therapeutic Intervention of Tinea Cruris (Jock Itch). Journal of Nursing, 71(03). https://doi.org/10.5281/zenodo.10811676

31. Mishra, N., Alagusundaram, M., Sinha, A., Jain, A. V., Kenia, H., Mandal, S., & Sharma, M. (2024). Analytical Method, Development and Validation for Evaluating Repaglinide Efficacy in Type Ii Diabetes Mellitus Management: A Pharmaceutical Perspective. Community Practitioner, 21(2), 29–37. https://doi.org/10.5281/zenodo.10642768

32. Singh, M., Aparna, T. N., Vasanthi, S., Mandal, S., Nemade, L. S., Bali, S., & Kar, N. R. (2024). Enhancement and Evaluation of Soursop (Annona Muricata L.) Leaf Extract in Nanoemulgel: a Comprehensive Study Investigating Its Optimized Formulation and Anti-Acne Potential Against Propionibacterium Acnes, Staphylococcus Aureus, and Staphylococcus Epidermidis Bacteria. Community Practitioner, 21(1), 102–115. https://doi.org/10.5281/zenodo.10570746

33. Gupta, N., Negi, P., Joshi, N., Gadipelli, P., Bhumika, K., Aijaz, M., Singhal, P. K., Shami, M., Gupta, A., & Mandal, S. (2024). Assessment of Immunomodulatory Activity in Swiss Albino Rats Utilizing a Poly-Herbal Formulation: A Comprehensive Study on Immunological Response Modulation. Community Practitioner, 21(3), 553–571. https://doi.org/10.5281/zenodo.10963801

34. Mandal S, Vishvakarma P, Bhumika K. Developments in Emerging Topical Drug Delivery Systems for Ocular Disorders. Curr Drug Res Rev. 2023 Dec 29. doi: 10.2174/0125899775266634231213044704. Epub ahead of print. PMID: 38158868.

35. Abdul Rasheed. A. R, K. Sowmiya, S. N., & Suraj Mandal, Surya Pratap Singh, Habibullah Khallullah, N. P. and D. K. E. (2024). In Silico Docking Analysis of

Phytochemical Constituents from Traditional Medicinal Plants: Unveiling Potential Anxiolytic Activity Against Gaba, Community Practitioner, 21(04), 1322–1337. https://doi.org/10.5281/zenodo.11076471